In line with this finding, tumor cell surface membrane protein analysis indicated GPR173 in combination with neurotrophic tyrosine kinase 1 or ALK (anaplastic lymphoma kinase) to be a target for specific immunotherapy treating neuroblastoma [37]. This evidence concerns the gene ALK and neuroblastoma.